Key result
Obesity (BMI ≥35 kg/m2) in patients undergoing transcarotid revascularization did not significantly increase the 30-day risk of stroke or death compared to non-obese patients (3.1% vs 3.0%, P>0.99).
Why the study?
The perioperative risks associated with transcarotid revascularization in obese patients were not well defined.
Does obesity (BMI ≥35 kg/m2) increase perioperative risks and adverse events in patients undergoing transcarotid revascularization (TCAR)?
Cohort (n=793)
Yes
Does obesity (BMI ≥35 kg/m2) increase perioperative risks and adverse events in patients undergoing transcarotid revascularization (TCAR)?
Absolute Event Rate: 3.1% vs 3%
p-value: p=>0.99
Transcarotid revascularization can be performed safely in obese patients with no significant increase in intraoperative complexity or perioperative adverse events compared to non-obese patients.
Suggests obesity alone should not preclude transcarotid artery revascularization; leaves.
Objective Transcarotid revascularization (TCAR) is a minimally invasive hybrid surgical carotid stenting technique which utilizes cerebral flow reversal as embolic protection during carotid lesion manipulation. This investigation was performed to define the perioperative risks associated with this operation in the obese patient. Methods A retrospective review of tandem carotid revascularization databases maintained at two high-volume health systems was performed to capture all TCARs performed between 2015 and 2022. A threshold of body mass index of 35 kg/m 2 defined the “obese” patient. Demographics, intraoperative, perioperative, and follow-up characteristics were compared using univariate analysis. Results We performed 793 TCAR procedures that qualified for study inclusion within the prespecified time. After applying our obesity definition, 129 patients qualified as obese and were compared to the remainder. There were no significant differences in baseline demographics as comparable Charlson Comorbidity Indices were noted between groups; however, obese patients had a significantly higher prevalence of hypertension, hyperlipidemia, and diabetes. Intraoperative, case complexity in the obese patients did not seem to be increased, as measured by operative time (68.4 ± 23.0 vs 64.2 ± 25.8 min, p = 0.09), fluoroscopic time (4.9 ± 3.2 vs 4.6 ± 3.6 min, p = 0.38), and estimated blood loss (40.6 ± 49.0 vs 46.6 ± 49.4 min, p = 0.22). Similarly, no disparities were observed with respect to ipsilateral stroke (3.1 vs. 1.7%, p = 0.29), contralateral stroke (0 vs. 0.2%, p > 0.99), death (0 vs. 1.1%, p = 0.61), and stroke/death (3.1 vs. 3.0%, p > 0.99) in the 30-day perioperative period. Both cohorts were followed for approximately 1 year (12.0 ± 13.4 vs 11.6 ± 13.4 months, p = 0.76). During this period, rates of ipsilateral stroke (3.1% vs. 2.7%, p > 0.99), contralateral stroke (1.1 vs. 0.8%, p > 0.99), and death (4.7 vs. 6.2%, p = 0.68) were similar. Conclusions TCAR performed in the obese population was not more challenging by intraoperative characteristics and did not result in a statistically higher incidence of adverse events in the perioperative phase.
No takes yet. Share an insight, caveat, or question.
Dakour-Aridi et al. (2022) conducted a cohort in Carotid artery disease requiring revascularization (n=793). Obesity (BMI ≥ 35 kg/m2) vs. Non-obese patients (BMI < 35 kg/m2) was evaluated on 30-day stroke or death (p=>0.99). Obesity (BMI ≥35 kg/m2) in patients undergoing transcarotid revascularization did not significantly increase the 30-day risk of stroke or death compared to non-obese patients (3.1% vs 3.0%, P>0.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: